Evidence map›Paper›PMID 40943552›Full record

ReviewInternational journal of molecular sciences2025

MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression.

Clelia Asero, Maria Stella Franzè, Irene Cacciola, Sebastiano Gangemi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Clelia AseroDivision of Medicine and Hepatology, University Hospital of Messina, 98124 Messina, Italy.ORCID 0000-0003-0427-6963
Maria Stella FranzèDivision of Medicine and Hepatology, University Hospital of Messina, 98124 Messina, Italy.ORCID 0000-0002-9815-5275
Irene CacciolaDivision of Medicine and Hepatology, University Hospital of Messina, 98124 Messina, Italy.ORCID 0000-0001-7721-6799
Sebastiano GangemiDepartment of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.

Funding

Ministero dell'università e della ricerca PRIN_2022PNRR_P2022KCHLN_002
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most prevalent cause of chronic liver disease worldwide. Its pathogenesis is complex and not yet fully elucidated but is commonly explained by the "multiple hit" hypothesis, which suggests that pathological behaviours interact with an unfavourable genetic background and the presence of cardiovascular comorbidities. Recent evidence has highlighted a potential role of the gut microbiota in the onset and progression of MASLD to metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC), potentially driven by epigenetic modifications mediated by microRNAs (miRNAs). MiRNAs are small, non-coding RNAs that regulate gene expression both intra- and extracellularly. Notably, emerging data suggests a bidirectional communication between the gut microbiota and the host, mediated by miRNAs via exosomes and outer membrane vesicles. The primary aim of this review is to explore the epigenetic crosstalk between the host and the gut microbiota through miRNA expression, with the goal of identifying specific pathways involved in MASLD development and natural history. A secondary objective is to evaluate the potential applications of artificial intelligence in the analysis of these complex host-microbiota interactions, to standardize the evaluation of microbiota and to create a model of the epigenetic changes in metabolic liver disease.

Indexed as

Fatty LiverGastrointestinal MicrobiomeMicroRNAsNon-alcoholic Fatty Liver DiseaseAnimalsCarcinoma, HepatocellularDisease ProgressionEpigenesis, GeneticHumansLiver NeoplasmsMicroRNAsartificial intelligenceexosomesmetabolic dysfunction-associated steatotic liver diseasemicrobiotamicroRNAs

Identifiers

PMID40943552
PMCPMC12429628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.